This recombinant monoclonal antibody is developed as a research-grade biosimilar to APG-808, targeting the interleukin-4 receptor (IL4R). IL4R is a type I transmembrane protein that serves as a component of receptor complexes for both IL-4 and IL-13, two critical cytokines involved in type 2 immune responses. Upon ligand binding, IL4R initiates JAK-STAT signaling pathways that regulate allergic inflammation, IgE production, and alternative macrophage activation. Dysregulated IL4R signaling plays a central role in the pathogenesis of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and other type 2 inflammatory conditions.
APG-808 represents a therapeutic antibody designed to block IL4R signaling by preventing both IL-4 and IL-13 from engaging their respective receptor complexes. This biosimilar antibody provides researchers with a valuable tool for investigating IL4R-mediated pathways, studying type 2 inflammation mechanisms, and exploring therapeutic interventions in allergic and inflammatory disease models. It supports studies examining immune cell differentiation, cytokine signaling networks, and the molecular basis of atopic disorders.
Email: support@cusabio.com
Distributors Worldwide